{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:29:13Z","timestamp":1788866953619,"version":"build-2803163510"},"reference-count":48,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Marmara University Scientific Research Projects Unit","award":["SAG-C-DRP-090217-0043"],"award-info":[{"award-number":["SAG-C-DRP-090217-0043"]}]},{"award":["SAG-C-DRP-090217-0043"],"award-info":[{"award-number":["SAG-C-DRP-090217-0043"]}],"id":[{"id":"https:\/\/ror.org\/02kswqa67","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Due to the serious side effects and the resistant phenotype acquired by tumors, cisplatin has limited clinical efficacy. The current study aims to investigate the potential of disulfide-bridged phthalocyanines to make breast cancer cells (MCF-7) more sensitive to cisplatin. For this purpose, a novel disulfide-bridged dimeric phthalocyanine complex with a therapeutically active wavelength absorbance value that is activatable in cancer cells was synthesized and encapsulated in liposome nanoparticles. Methods: The synthesized phthalocyanine was characterized using FTIR, UV\u2013visible, and MALDI-TOF-MS techniques; liposome nanoparticles containing the synthesized phthalocyanine were characterized using a particle size analyzer and were tested on MCF-7 breast cancer cell lines using MTT and flow cytometric assays. Results: The results have illustrated that GSH cleavages disulfide bonds of the synthesized disulfide-bridged dimeric phthalocyanine complex with quite favorable characteristics for photodynamic therapy, such as a therapeutically active wavelength absorbance value (685 nm), and disulfide-bridged phthalocyanine (ASG20)-containing liposome nanoparticles have quite favorable characteristics (average size of 167.6 nm and polydispersity index of 0.108) for biomedical applications. As evidenced by MTT and flow cytometric assays, by causing extra decreases in the viability of breast cancer cells (p &lt; 0.01), pre-treatment of the breast cancer cells with photodynamic therapy using the activatable liposome nanoparticles significantly (p &lt; 0.01) enhanced the anticancer activity of cisplatin in high and low doses. Conclusions: In conclusion, the activatable liposome nanoparticles containing disulfide-bridged dimeric phthalocyanine complexes can enable much more effective cisplatin-based therapies for breast cancer by overcoming the handicaps of cisplatin, drug resistance (by decreasing intracellular GSH levels), and serious side effects (by enabling the usage of lower doses of cisplatin in chemotherapy).<\/jats:p>","DOI":"10.3390\/ph19071052","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:27:23Z","timestamp":1783520843000},"page":"1052","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combination Therapy with Cisplatin and Activatable Liposomes on Breast Cancer Cells"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2692-5434","authenticated-orcid":false,"given":"Kurtulus","family":"Gokduman","sequence":"first","affiliation":[{"name":"Institute of Biomedical Engineering, Bogazici University, 34684 Istanbul, T\u00fcrkiye"},{"name":"BIOMEDRIC LLC, Pittsfield, MA 01201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6424-7411","authenticated-orcid":false,"given":"Asiye Gok","family":"Yurttas","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Faculty of Medicine, Istanbul Atlas University, 34403 Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Cecati, M., Pozzi, V., Pompei, V., Schiavoni, V., Fumarola, S., Romagnoli, A., Tossetta, G., Montana, A., Polizzi, A., and Sartini, D. (2026). Cisplatin as a Xenobiotic Agent: Molecular Mechanisms of Actions and Clinical Applications in Oncology. J. Xenobiotics, 16.","DOI":"10.3390\/jox16010009"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Chen, S.H., and Chang, J.Y. (2019). New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174136"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.7150\/thno.46460","article-title":"Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41523-022-00406-0","article-title":"Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer","volume":"8","author":"Telli","year":"2022","journal-title":"npj Breast Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drup.2015.11.003","article-title":"Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation","volume":"24","author":"Ferreira","year":"2016","journal-title":"Drug Resist. Updat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2005.08.046","article-title":"MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma","volume":"100","author":"Guminski","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_8","first-page":"279","article-title":"Role of transporter genes in cisplatin resistance","volume":"22","author":"Konkimalla","year":"2008","journal-title":"Vivo"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.2217\/nnm-2019-0126","article-title":"Sensitization of cisplatin-resistant ovarian cancer cells by magnetite iron oxide nanoparticles: An in vitro study","volume":"14","author":"Gokduman","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mu, W., Zhi, Y., Zhou, J., Wang, C., Chai, K., Fan, Z., and Lv, G. (2024). Endoplasmic reticulum stress and quality control in relation to cisplatin resistance in tumor cells. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1419468"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e10608","DOI":"10.1016\/j.heliyon.2022.e10608","article-title":"Cisplatin for cancer therapy and overcoming chemoresistance","volume":"8","author":"Ranasinghe","year":"2022","journal-title":"Heliyon"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1002\/mco2.603","article-title":"Photodynamic therapy for cancer: Mechanisms, photosensitizers, nanocarriers, and clinical studies","volume":"5","author":"Zhao","year":"2024","journal-title":"MedComm"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/cbdd.12792","article-title":"Design features for optimization of tetrapyrrole macrocycles as antimicrobial and anti-cancer photosensitizers","volume":"89","author":"Mroz","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"105575","DOI":"10.1016\/j.biocel.2019.105575","article-title":"Zinc(II) phthalocyanines as photosensitizers for antitumor photodynamic therapy","volume":"114","author":"Roguin","year":"2019","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1016\/j.apsb.2024.10.015","article-title":"Recent advances in reactive oxygen species (ROS)-responsive drug delivery systems for photodynamic therapy of cancer","volume":"14","author":"Hu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"van Straten, D., Mashayekhi, V., de Bruijn, H.S., Oliveira, S., and Robinson, D.J. (2017). Oncologic photodynamic therapy: Basic principles, current clinical status and future directions. Cancers, 9.","DOI":"10.3390\/cancers9020019"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1572-1000(05)00060-8","article-title":"Mechanisms in photodynamic therapy: Part three- Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction","volume":"2","author":"Castano","year":"2005","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ccr.2017.08.003","article-title":"Phthalocyanines as medicinal photosensitizers: Developments in the last five years","volume":"379","author":"Li","year":"2019","journal-title":"Coord. Chem. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.18632\/oncotarget.27596","article-title":"Review: Organic nanoparticle based active targeting for photodynamic therapy treatment of breast cancer cells","volume":"11","author":"Montaseri","year":"2020","journal-title":"Oncotarget"},{"key":"ref_21","first-page":"2309","article-title":"Development and validation of a fast and selective HPLC method for the determination of amphotericin B in nose-to-brain nanoliposome","volume":"10","author":"Rios","year":"2021","journal-title":"Lett. Appl. NanoBioScience"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1124\/pr.115.012070","article-title":"Lipid-based drug delivery systems in cancer therapy: What is available and what is yet to come","volume":"68","author":"Yingchoncharoen","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_23","first-page":"304","article-title":"Liposomes Loaded with Activatable Disulfide Bridged Photosensitizer: Towards Targeted and Effective Photodynamic Therapy on Breast Cancer Cells","volume":"12","author":"Yurttas","year":"2022","journal-title":"Biointerface Res. Appl. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e2309054","DOI":"10.1002\/smll.202309054","article-title":"A Dual-Responsive Morphologically-Adaptable Nanoplatform for Targeted Delivery of Activatable Photosensitizers in Precision Photodynamic Therapy","volume":"20","author":"Jiao","year":"2024","journal-title":"Small"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1021\/ja056726i","article-title":"Glutathione-mediated delivery and release using monolayer protected nanoparticle carriers","volume":"128","author":"Hong","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11223","DOI":"10.1039\/C7DT02086D","article-title":"A cell-selective glutathione-responsive tris(phthalocyanine) as a smart photosensitiser for targeted photodynamic therapy","volume":"46","author":"Chow","year":"2017","journal-title":"Dalton Trans."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e09641","DOI":"10.1002\/adma.202509641","article-title":"De Novo Construction of Glutathione Activatable Photosensitizers Boosts Sequential Photoacoustic and Fluorescence Imaging and Precise Photodynamic Therapy","volume":"38","author":"Fu","year":"2026","journal-title":"Adv. Mater."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"38916","DOI":"10.1021\/acsami.4c05181","article-title":"A Nanoencapsulated Ir(III)-Phthalocyanine Conjugate as a Promising Photodynamic Therapy Anticancer Agent","volume":"16","author":"Bonelli","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.2174\/1389450117666160502151707","article-title":"Strategies targeting DNA topoisomerase I in cancer chemotherapy: Camptothecins, nanocarriers for camptothecins, organic non-camptothecin compounds and metal complexes","volume":"17","author":"Gokduman","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"111099","DOI":"10.1016\/j.msec.2020.111099","article-title":"Multifunctional nanoparticles as photosensitizer delivery carriers for enhanced photodynamic cancer therapy","volume":"115","author":"Zhang","year":"2020","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: Recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnology"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ciftci, F., \u00d6zarslan, A., Kantarci, \u0130., Yelkenci, A., Tavukcuoglu, O., and Ghorbanpour, M. (2025). Advances in Drug Targeting, Drug Delivery, and Nanotechnology Applications: Therapeutic Significance in Cancer Treatment. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17010121"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.dyepig.2013.08.018","article-title":"Preparation, characterization, and in vitro phototoxic effect of zinc phthalocyanine cucurbit [7]uril complex encapsulated into liposomes","volume":"100","author":"Bolfarini","year":"2014","journal-title":"Dye. Pigm"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2174\/15734137113099990076","article-title":"Camptothecin anticancer drug loaded iron oxide micro and nanoparticles: Tuning targeted and sustained release of the drug in bioactive form","volume":"9","author":"Gokduman","year":"2013","journal-title":"Curr. Nanosci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/IJN.S68861","article-title":"Liposomes as nanomedical devices","volume":"10","author":"Bozzuto","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"14496","DOI":"10.1039\/C6RA28633J","article-title":"Superparamagnetic iron oxide nanoparticles dispersed in Pluronic F127 hydrogel: Potential uses in topical applications","volume":"7","author":"Goncalves","year":"2017","journal-title":"RSC Adv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"22243","DOI":"10.3390\/ijms160922243","article-title":"Characterization, quantification, and determination of the toxicity of iron oxide nanoparticles to the bone marrow cells","volume":"16","author":"Paik","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1166\/jnn.2020.17152","article-title":"In vitro investigation of therapeutic potential of bare magnetite (Fe3O4) nanoparticles (\u2264100 ppm) on hepatocellular carcinoma cells","volume":"20","author":"Gokduman","year":"2020","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.33263\/LIANBS92.10491057","article-title":"Comparison of the effect of magnetite (Fe3O4) iron oxide nanoparticles on melanoma cells and healthy cells: An in vitro study","volume":"9","author":"Gokduman","year":"2020","journal-title":"Lett. Appl. NanoBioScience"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1016\/j.biomaterials.2007.07.029","article-title":"Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential","volume":"28","author":"Patil","year":"2007","journal-title":"Biomaterials"},{"key":"ref_41","unstructured":"Babu, S. (2016). Chemical metrology methods for CMP quality. Advances in Chemical Mechanical Planarization (CMP), Woodhead Publishing."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ill\u00e9s, E., Szekeres, M., T\u00f3th, I.Y., Farkas, K., F\u00f6ldesi, I., Szab\u00f3, \u00c1., Iv\u00e1n, B., and Tomb\u00e1cz, E. (2018). PEGylation of superparamagnetic iron oxide nanoparticles with self-organizing polyacrylate-PEG brushes for contrast enhancement in MRI diagnosis. Nanomaterials, 8.","DOI":"10.3390\/nano8100776"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"45597","DOI":"10.18632\/oncotarget.17316","article-title":"Enhanced antitumor efficacy of cisplatin for treating ovarian cancer in vitro and in vivo via transferrin binding","volume":"8","author":"Peng","year":"2017","journal-title":"Oncotarget"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Cheng, L., Jin, C., Lv, W., Ding, Q., and Han, X. (2011). Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025433"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.addr.2013.09.019","article-title":"Nanomedicine therapeutic approaches to overcome cancer drug resistance","volume":"65","author":"Markman","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3892\/or.2015.4371","article-title":"Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell lines","volume":"35","author":"Baharuddin","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.18632\/oncotarget.23187","article-title":"Metformin synergistically suppress tumor growth with doxorubicin and reverse drug resistance by inhibiting the expression and function of P-glycoprotein in MCF7\/ADR cells and xenograft models","volume":"9","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1011-1344(99)00008-1","article-title":"Photodynamic activities of silicon phthalocyanines against achromic M6 melanoma cells and healthy human melanocytes and keratinocytes","volume":"48","author":"Decreau","year":"1999","journal-title":"J. Photochem. Photobiol. B"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/7\/1052\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:28:24Z","timestamp":1783520904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/7\/1052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ph19071052"],"URL":"https:\/\/doi.org\/10.3390\/ph19071052","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}